Venrock Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
29
- Investments
-
1,038
- Portfolio
-
118
- Exits
-
478
Venrock General Information
Company Description
Founded in 1969, Venrock is a venture capital investment firm based in Palo Alto, California. The firm has additional offices in New York. The firm primarily focuses on technology and healthcare. The firm seeks to invest in companies operating in the technology, healthcare, consumer, cryptocurrency, cybersecurity, defense & aerospace, security & infrastructure, financial technology, software-as-a-service, and artificial intelligence sectors based in the United States region.
Business Details
Investor Status
Trade Association
Primary Investor Type
Other Investor Types
Corporate Office
- 3340 Hillview Avenue
- Silicon Valley
- Palo Alto, CA 94304
- United States
Venrock Investments & Acquisitions (1,038)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Adcendo | 25-Nov-2024 | Later Stage VC | Drug Discovery | Pre-Clinical Trials | ||
Cidara Therapeutics | 21-Nov-2024 | Biotechnology | Generating Revenue/Not Profitable | |||
Metsera | 13-Nov-2024 | Drug Discovery | Clinical Trials - Phase 2 | |||
Crescent Biopharma | 29-Oct-2024 | Drug Discovery | Generating Revenue | |||
enGene (Biotechnology) | 25-Oct-2024 | Biotechnology | Clinical Trials - General | |||
Scope3 | 10-Oct-2024 | Media and Information Services (B2B) | Generating Revenue | |||
Suki | 10-Oct-2024 | Enterprise Systems (Healthcare) | Generating Revenue | |||
Candid Therapeutics | 20-Aug-2024 | Drug Discovery | Clinical Trials - Phase 1 | |||
Tenax Therapeutics | 12-Aug-2024 | PIPE | Pharmaceuticals | Generating Revenue/Not Profitable | ||
Vanilla | 12-Aug-2024 | Later Stage VC | Business/Productivity Software | Generating Revenue |
Venrock Exits (478)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Numerated | 21-Nov-2024 | Merger/Acquisition | |
Spyre Therapeutics | 19-Nov-2024 | ||
Upstream Bio | 11-Oct-2024 | ||
Viridian Therapeutics | 13-Sep-2024 | ||
Artiva | 19-Jul-2024 | ||
Running Tide | 19-Jun-2024 | ||
Graphite Bio | 20-Mar-2024 | ||
Carmot Therapeutics | 26-Jan-2024 | ||
Humanigen | 03-Jan-2024 | Bankruptcy: Admin/Reorg | |
Annexon Biosciences | 21-Dec-2023 | Public Investment 2nd Offering |
Venrock Fund Performance
Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
---|
Venrock Investments by Industry, Year, and Region
Venrock Co-Investors (635)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Logos Capital | 16 | ||||
Fidelity Management & Research | |||||
RA Capital Management | |||||
Janus Henderson Investors | |||||
OrbiMed |
Venrock FAQs
-
What is Venrock?
Founded in 1969, Venrock is a venture capital investment firm based in Palo Alto, California.
-
When was Venrock founded?
Venrock was founded in 1969.
-
Where is Venrock headquartered?
Venrock is headquartered in Palo Alto, CA.
-
What is Venrock's total asset value?
Venrock has around
in total assets under management. -
How many investments has Venrock made?
Venrock has made 1,038 investments.
-
What has Venrock invested in?
Venrock has made numerous investments in companies like Adcendo, Cidara Therapeutics, and Metsera within the Drug Discovery and Biotechnology industries.
-
What has Venrock invested in recently?
Venrock's latest investment was on 25-Nov-2024 in Adcendo, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »